Chapter 7 · Module 4

Calcium Channel Blockers & Diuretics

Mechanisms, subclass distinctions, metabolic effects, and combination strategies

Calcium Channel Blockers — DHP vs Non-DHP

Tissue Selectivity Is the Key Distinction

Dihydropyridine vs Non-Dihydropyridine Comparison

Feature	Dihydropyridine (DHP)	Non-Dihydropyridine (Non-DHP)
Tissue selectivity	Vascular smooth muscle (high selectivity)	Vascular + cardiac tissue (equal effect)
Heart rate	May increase (reflex tachycardia)	Decreases (negative chronotropy)
AV conduction	No significant effect	Slows (negative dromotropy)
Contractility	Minimal effect	Decreases (negative inotropy)
Main adverse effects	Peripheral edema, flushing, headache	Bradycardia, AV block, constipation (verapamil)
HFrEF	Safe — amlodipine preferred	Contraindicated
Atrial fibrillation rate control	Not used	Yes — diltiazem or verapamil
With beta-blockers	Acceptable	Contraindicated — risk of complete heart block
Prototype agents	Amlodipine, nifedipine (long-acting only), felodipine	Verapamil, diltiazem

Diuretic Subclasses — Site of Action & Clinical Role

Three Subclasses, Three Nephron Segments

Diuretic Quick Reference

Subclass	Site / Transporter	Preferred Agent	Primary Role	Calcium Effect
Thiazide / thiazide-like	Distal convoluted tubule — NCC (sodium-chloride cotransporter)	Chlorthalidone (longest half-life, best evidence)	First-line antihypertensive; isolated systolic hypertension in elderly	Increases reabsorption (useful in nephrolithiasis)
Loop	Thick ascending limb — NKCC2 (sodium-potassium-2-chloride cotransporter)	Furosemide, torsemide	Advanced CKD (eGFR below 30); heart failure volume overload; most potent	Increases excretion
Potassium-sparing / MRA	Collecting duct — MR (mineralocorticoid receptor) or ENaC (epithelial sodium channel)	Spironolactone (PATHWAY-2 best 4th-line for resistant HTN); eplerenone (selective, fewer hormonal effects)	Resistant hypertension; primary aldosteronism; HFrEF (guideline-directed)	No significant effect

Thiazide Metabolic Adverse Effects

Most Common

Hypokalemia

10–30% of patients
Increased Na delivery to collecting duct → aldosterone-mediated K secretion
Risk of arrhythmias with digoxin or cardiac disease
Correct Mg first — Mg depletion impairs K conservation

Metabolic

Hyperuricemia

Reduced uric acid excretion (tubular competition) + volume contraction
Asymptomatic hyperuricemia alone: not a contraindication
With gout: use losartan as RAAS partner (uricosuric effect)

Glucose

New-Onset Diabetes

Dose-dependent; most prominent above HCTZ 25 mg/day
Mechanism: hypokalemia impairs insulin secretion
Chlorthalidone 12.5 mg: modest effect
Indapamide: most favorable metabolic profile

Electrolyte

Hyponatremia

Most common in elderly women
Volume depletion stimulates ADH → free water retention
Chlorthalidone carries higher risk than HCTZ (longer half-life)
Monitor closely in first weeks of therapy

Combination Strategies

Preferred Combinations

Evidence-Based Pairings

CCB + RAAS inhibitor: ACCOMPLISH trial — 20% RRR vs RAAS + HCTZ; synergistic (CCB reduces TPR; RAAS inhibitor blunts reactive RAAS and reduces edema)
RAAS inhibitor + thiazide: diuretic activates RAAS, amplifying RAAS inhibitor effect; RAAS inhibitor blunts hypokalemia
Triple therapy (CCB + RAAS inhibitor + thiazide): standard of care for hypertension uncontrolled on dual therapy

Combinations to Avoid

Non-DHP CCB + beta-blocker: both suppress SA and AV nodes → complete heart block risk — contraindicated

ACEi + ARB (dual RAAS blockade): ONTARGET — no benefit, more AKI and hyperkalemia

Thiazide + loop diuretic: excessive natriuresis and volume depletion — specialist use only